Novartis Provides Phase III Update on Myotonic Dystrophy Treatment

The company released progress details on the HARBOR study evaluating delpacibart etedesiran, a novel therapy aimed at treating myotonic dystrophy type 1.

8 Sept, 05:00 — 8 Sept, 05:00

Post Share

Sources

Showing 1 of 1 sources

taiwan-newsMostly Factual5h ago

Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1) - Taiwan News

Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1) Taiwan News

Read full article →

Novartis Provides Phase III Update on Myotonic Dystrophy Treatment

Sources

Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1) - Taiwan News

Related Stories

Secondhand Smoke Causes Nearly 1.7 Million Deaths Globally in 2023

Pamela Anderson Opens Up About Her 1990s Hepatitis C Diagnosis and Recovery

Teen Girl Intubated After Electric Scooter Crash in Tinos

Emma Bonino Hospitalized in Rome in Serious Condition